Introduction
Rheumatoid arthritis (RA) is a systemic disease characterized by circulating autoantibodies, synovial inflammation, pannus formation, and cartilage and bone destruction in affected joints. Initiation of the disease involves the systemic dysregulation of T and B lymphocytes, which results in immune responses directed against self-antigens.
During the chronic inflammatory phase of the disease, autoantibodies and immune complexes further activate a variety of cells such as neutrophils, monocytes/macrophages, dendritic cells, and mast cells that infiltrate the synovium and release proinflammatory cytokines and matrix metalloproteases, leading to cartilage destruction. Synovial hyperplasia leads to the formation of a pannus that invades the surrounding cartilage and bone, and inflammation enhances the activity of resident osteoclasts, leading to bone erosion 1, 2 .
During the multi-step pathogenesis of RA, a host of intracellular signalling kinases are involved in initiation, inflammation, and bone resorption, including Janus kinase 1/3 (JAK1/3) in T cells and, in B cells, spleen tyrosine kinase (SYK) and Bruton's tyrosine kinase (BTK). These mediate cell survival and the inflammatory response 2 . As such, RA has been a disease of interest for tyrosine kinase modulation, with small molecule JAK inhibitors leading the way in this approach to the clinical treatment of patients with RA. Modulation of the JAK/signal transducers and activators of transcription (STAT) pathway has proven to be effective in these patients, as evidenced by tofacitinib, which was approved in November 2012 for the treatment of patients with moderateto-severe RA with an inadequate response to or intolerance of methotrexate. Tofacitinib primarily inhibits JAK1 and JAK3, and, to a lesser extent, JAK2 3, 4 . Multiple JAK inhibitors targeting different JAK homodimers are also being developed for patients with RA. The introduction of small molecule inhibition to RA treatment has led to clinical trials of other targeted therapies in various phases of development. This review focuses primarily on inhibitors of the B-cell kinases SYK and BTK that are currently in clinical development.
Discussion
The authors have referenced some of their own studies in this review. These referenced studies have been conducted in accordance with the Declaration of Helsinki (1964) and the protocols of these studies have been approved by the relevant ethics committees related to the institution in which they were performed. All human subjects, in these referenced studies, gave informed consent to participate in these studies.
Clinical Significance of B Cells in RA
Ample clinical data support the role of B cells in the pathogenesis of RA. Rituximab, a monoclonal antibody targeting CD20 expressed on B cells, was the first B-cell-targeted therapy to gain approval for treatment of patients with RA. It was developed with the intention of depleting autoreactive B cells in order to reduce the production of pathogenic autoantibodies such as rheumatoid factor 5 . The efficacy of rituximab was established in patients who still had active disease despite being treated with methotrexate 6,7 and in patients who were refractory or intolerant to anti-tumour necrosis cells, and reduced serum Ig levels 26,31 . Since RA is characterized by polyclonal B-cell activation that gives rise to B-cell expansion and the production of autoantibodies, BTK is a uniquely attractive target for selective B-cell inhibition in RA.
BTK is also expressed in specific types of myeloid cells that are known to be key players in the chronic inflammatory phase of RA, such as monocytes, macrophages, neutrophils, and mast cells. Loss of BTK in macrophages and myeloid cells has been linked to compromised inflammatory responses.
BTK is activated following FϲγR/FϲεR crosslinking by immune complexes in these cells 32, 33, 34, 35 . Lacking BTK, xid mice have reduced FϲεR-dependent mast-cell degranulation 33 and impaired macrophage function 34, 36 , including impaired TNF-α production 37 . Accordingly, xid mice have demonstrated resistance to disease manifestations in CIA models 38 , and BTK has been shown to be important for murine autoantibody production 39, 40, 41 . The involvement of BTK not only in B cells but also in these myeloid cells provides further support for the potential role of BTK inhibition in treating RA.
SYK Inhibition in RA
Fostamatinib (R788) was developed as an orally bioavailable small-molecule prodrug that is metabolized to R406, an active SYK inhibitor (Table 1 ). It has been tested in different populations of patients with RA with mixed results 17 . Three phase 2 studies have reported results with fostamatinib treatment in patients with RA. Two of the studies examined the effect of fostamatinib therapy in patients with active RA who had an inadequate response to methotrexate 42, 43 . One of these was a 12-week, randomized, placebocontrolled study that enrolled 189 patients in a 3:1 ratio to receive fostamatinib in an ascending-dose manner versus placebo 42 . The primary endpoint was the ACR20 response rate at week 12. Significantly more patients in two of the fostamatinib dosing groups (100 mg and 150 mg twice daily) achieved an ACR20 response (65% and 72%, respectively) than in the placebo group (38%; P < 0.01 for both doses vs placebo). Higher percentages of patients from these two dosing groups also achieved ACR50 and ACR70 responses and Disease Activity Score in 28 joints (DAS28) scores <2.6 than the placebo group.
The second phase 2 study enrolled 457 patients with active RA who had an inadequate response to methotrexate. These patients were randomized to fostamatinib or placebo for 6 months, with the primary outcome of ACR20 response at month 6 43 . The fostamatinib doses of 100 mg twice daily and 150 mg twice daily were significantly superior to placebo with regard to the primary endpoint (ACR20 response rates of 67% and 57%, respectively, vs 35%; P < 0.001 for both doses vs placebo) as well as ACR50 (43% and 32% vs 19%; P < 0.001 for 100-mg dose vs placebo, P = 0.007 for 150-mg dose vs placebo) and ACR70 (28% and 14% vs 10%; P < 0.001 for 100-mg dose vs placebo, P = 0.34 for 150-mg dose vs placebo). This study confirmed that ACR20, ACR50, and ACR70 responses could be maintained for 6 months with fostamatinib therapy in this population of patients with RA.
Subsequently, in OSKIRA-1, a phase 3 trial that compared fostamatinib with placebo in 923 patients with RA who had an inadequate response to methotrexate, the individual fostamatinib-treated groups had 24-week ACR20 response rates that were significantly higher than those seen in the placebo group; however, the study failed to achieve the co-primary endpoint, which was to achieve a significantly different modified Total Sharp Score at 24 weeks between the fostamatinib and placebo groups 44 .
Fostamatinib has also been tested in patients with active RA who did not respond to biologic agents 45 . A 3-month, randomized, placebocontrolled, phase 2 study in a total of 219 patients with RA reported no significant differences achieved in the ACR20, ACR50, or ACR70 response levels at 3 months between patients receiving fostamatinib and those given placebo.
Contrary to the previous phase 2 studies, the primary endpoint of ACR20 response at month 3 was not significantly different between the fostamatinib group and the placebo group. The authors noted that this endpoint may have been compromised by the study's difficultto-treat patient population, as well as by differences in baseline disease activity and distribution of patients with refractory disease between the fostamatinib and placebo groups.
Additional phase 3 trials with fostamatinib include OSKIRA-2, which studied patients with RA who had inadequate responses to diseasemodifying antirheumatic drugs (DMARDs) 46 , and OSKIRA-3, which studied patients with RA who had inadequate responses to methotrexate and a single TNF-α antagonist 47 . Both of these studies demonstrated ACR20 response rates at 24 weeks that were significantly higher for the fostamatinib-treated groups than they were with placebo, but no further phase 3 development with fostamatinib in RA has occurred since the results of these trials 48 . 50 . It has also demonstrated therapeutic activity in animal models of RA 49 . Ibrutinib potently and dosedependently reversed clinical arthritis and prevented cartilage and bone erosion in an aggressive late-stage CIA model and a CAIA model (Table 1) . In both models, anti-collagen antibodies produced by B cells formed immune complexes that engaged and activated the Fϲ macrophages, neutrophils, and mast cells, resulting in the infiltration or trafficking of these effector cells to antigen sites, such as the joints, where they released mediators that initiated synovitis, bone erosion, and pain 51, 52, 53 .
BTK Inhibition in RA
In an RPA assay in which neutrophils, macrophages, and mast cells acted as the key effector cells independently of the complement system, ibrutinib potently inhibited acute vasculitis mediated by immune complexes and FϲγR 54 . Collectively, these studies established the dose-dependent inhibition of ibrutinib on immune complex mediated inflammation in vivo.
BTK inhibition by ibrutinib has also been shown to inhibit cytokine and chemokine release upon FϲγR activation of monocytes and macrophages, as well as upon FϲεR activation of mast cells. In both CIA and CAIA models, ibrutinib inhibited clinical inflammation and pannus formation and protected against cartilage and bone damage. Mechanistically, ibrutinib potently inhibited the release of FϲγR-induced cytokines such as TNF-α, interleukin (IL)-6, IL-1β and monocyte chemoattractant protein 1 (MCP-1) in monocytes, albeit less potently in macrophages. Additional benefit in the CIA model might have been derived from the inhibition of RANKL-induced osteoclastic differentiation, as suggested by findings that BTK and Tec are key downstream elements in RANK signalling 55 .
Following ibrutinib treatment, Shinohara et al found a nearly complete inhibition of infiltrating cells (neutrophils and macrophages) in the synovial joints of mice. Cytokines and chemokines such IL-1β, IL-6, TNF-α, and MCP-1, and MCP-1 were also potently suppressed, consistent with in vitro results with primary monocytes and macrophages ( Figure  1 ).
In combination with the in vitro studies with human primary cells and with preclinical data for other inhibitors of BTK (Table 1) , these results suggest that BTK inhibition affects multiple cell types that contribute to the pathogenesis of RA, and that it is highly effective in models of several inflammatory diseases, including CIA, CAIA, and RPA. Inhibition of BTK by ibrutinib or other molecules thus constitutes a promising direction for therapeutic trials in diseases such as RA and other immune complex-mediated inflammatory diseases.
Conclusion
Biologic therapies such as rituximab that modulate the contribution of B cells to inflammatory pathways associated with RA are now used in clinical practice. Monoclonal antibodies and related biologics that are administered intravenously or subcutaneously have been the first targeted therapies for the treatment of patients with RA.
The regulatory approval of tofacitinib as a small-molecule inhibitor of the JAK-STAT pathway, however, has opened the path for the development of other targeted oral RA therapies. 
